Commercial Assessment Of The Chronic Kidney Disease (CKD) Market 2026-2036: Diagnosis Rates Rise And Treatment Options Expand
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The chronic kidney disease (CKD) market is expected to expand through 2036, driven by an aging population, earlier diagnosis, increasing disease prevalence, and wider adoption of combination cardiorenal therapies. The report provides a comprehensive assessment of CKD epidemiology, treatment practices, marketed therapies, pipeline development, competitive dynamics, and commercial opportunities across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
According to analysis, approximately 82.5 million prevalent CKD cases and nearly 14.5 million diagnosed prevalent cases were recorded across the 7MM in 2025. The patient population is projected to increase during the 2026-2036 forecast period, primarily due to demographic aging and the growing burden of diabetes, hypertension, and cardiovascular disease. In the United States, more than one in seven adults-approximately 37 million people-are estimated to have CKD, with prevalence rising substantially among adults aged 65 and older.
Type 2 diabetes remains a leading contributor to CKD, accounting for approximately 40% of US cases. Hypertension is another major risk factor, with an estimated 23 million Americans affected by both hypertension and CKD. Expanded screening among high-risk populations, supported by estimated glomerular filtration rate, urinary albumin-to-creatinine ratio, cystatin C, and albuminuria testing, is improving diagnostic accuracy and identifying patients at earlier disease stages.
CKD Epidemiology Highlights
- The United States accounted for approximately 26% of diagnosed prevalent CKD cases in the 7MM in 2025, representing around 3.8 million patients. Germany recorded the highest diagnosed prevalence among the EU4 and the United Kingdom, while Italy reported the lowest. Stage III represented the largest diagnosed CKD segment in the United States, with approximately 1.8 million cases in 2025. US epidemiology showed a female predominance, with approximately 2.1 million diagnosed cases among women and 1.7 million among men. Hyperparathyroidism was the most frequently reported complication among selected CKD-associated conditions, followed by anemia and metabolic acidosis.
Changing Chronic Kidney Disease Treatment Landscape
CKD management increasingly follows a multi-pathway treatment strategy designed to slow progression to kidney failure, reduce cardiovascular risk, and manage complications such as anemia and mineral bone disease. Renin-angiotensin system blockade, lifestyle intervention, and blood pressure management remain important components of care. However, sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists are now central to the evolving standard of care.
Empagliflozin (JARDIANCE), developed by Boehringer Ingelheim and Eli Lilly, and dapagliflozin (FARXIGA/FORXIGA), developed by AstraZeneca, have established broad roles in CKD treatment. Finerenone (KERENDIA), developed by Bayer, addresses residual renal and cardiovascular risk in adults with CKD associated with type 2 diabetes. Increasing use of these therapies in additive regimens is expected to remain a significant driver of CKD market growth.
Despite these advances, a substantial proportion of patients continue to experience disease progression. Persistent cardiorenal risk, delayed diagnosis, limited access to precision therapies, and the absence of treatments capable of consistently halting or reversing kidney damage remain significant unmet needs.
Emerging CKD Pipeline and Competitive Landscape
The chronic kidney disease pipeline is diversifying beyond established SGLT2 inhibitor and mineralocorticoid receptor antagonist regimens. Late-stage development programs are evaluating endothelin receptor antagonism, aldosterone synthase inhibition, APOL1-targeted therapies, and cell-based approaches.
AstraZeneca's investigational zibotentan and dapagliflozin combination targets complementary pathways involved in CKD progression. Phase IIb ZENITH-CKD findings demonstrated reductions in urinary protein markers of up to 52.5%, while final results from the Phase III ZENITH High Proteinuria study are expected in 2027.
Boehringer Ingelheim is developing vicadrostat in combination with empagliflozin. Phase II findings reported albuminuria reductions of up to 39.5% compared with placebo. Other notable pipeline assets include Mineralys Therapeutics' lorundrostat, ProKidney's rilparencel, Maze Therapeutics' MZE829 for APOL1-mediated kidney disease, and DISC-0974 for CKD-associated anemia.
In March 2026, Maze Therapeutics announced positive topline Phase II HORIZON trial results for MZE829, reporting clinical proof of concept in patients with APOL1-mediated kidney disease. Mineralys Therapeutics also continued to advance lorundrostat through clinical and regulatory milestones following data presented at ASN Kidney Week 2025.
CKD Market Growth Drivers and Commercial Opportunities
- Rising diagnosed prevalence: Greater screening of patients with diabetes, hypertension, and cardiovascular disease is expanding the addressable CKD treatment population. Combination cardiorenal therapy: Multi-drug regimens targeting complementary disease pathways are becoming increasingly important in clinical practice. Pipeline diversification: New mechanisms may address residual risk, genetically defined disease, advanced CKD, and CKD-related complications. Precision medicine: APOL1 inhibitors and other targeted approaches could create premium opportunities in underserved patient subgroups. Improved market access: Demonstrating durable kidney and cardiovascular outcomes will remain central to reimbursement, formulary positioning, and long-term uptake.
Report Coverage and Strategic Insights
The market report includes historical and forecast epidemiology from 2022 to 2036, therapy-level market assessments, drug uptake projections, peak patient-share analysis, pricing trends, reimbursement considerations, and analogue-based evaluation of emerging products. It also examines treatment algorithms, patient journeys, clinical development activity, market access barriers, and country-specific commercial opportunities.
The analysis incorporates perspectives from more than 15 key opinion leaders and subject-matter experts across leading clinical and academic institutions. SWOT and conjoint analyses evaluate emerging CKD therapies according to efficacy, safety, administration, launch timing, probability of success, and addressable patient population.
Overall, the CKD therapeutics market is moving toward combination-based and disease-modifying strategies layered onto an established SGLT2 inhibitor foundation. Empagliflozin, dapagliflozin, and finerenone are expected to remain major components of treatment, while endothelin-pathway combinations, aldosterone synthase inhibitors, APOL1-targeted drugs, and cell therapies could reshape the competitive landscape. Companies able to demonstrate meaningful renal outcomes, cardiovascular benefit, manageable safety profiles, and differentiated value are likely to secure stronger positions in the 7MM chronic kidney disease market through 2036.
A selection of companies mentioned in this report includes, but is not limited to:
- Boehringer Ingelheim Eli Lilly Bayer AstraZeneca Mineralys Therapeutics ProKidney Maze Therapeutics Regeneron Pharmaceuticals Disc Medicine
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment